Researchers at Adelaide University have developed a new drug, AU2-94, which has shown promising results in slowing cancer growth and protecting healthy blood-forming cells during chemotherapy. The drug, designed to be administered orally, aims to improve treatment options for patients with advanced and drug-resistant cancers, particularly prostate and breast cancers, who often cannot tolerate the debilitating side effects of chemotherapy.

Led by Professor Shudong Wang, the research team recently reached a significant milestone, with plans to advance the drug into human clinical trials. Two recently published studies have demonstrated positive outcomes for AU2-94 in two primary areas: inhibiting CDK4, an enzyme critical to cell division, and reducing chemotherapy-induced damage to bone marrow, where new blood cells are produced.

According to Professor Wang, these dual effects could provide substantial benefits in cancer treatment. "One is to slow cancer growth and the other is to help protect healthy, blood-forming cells during chemotherapy in some cancer types," she explained. Chemotherapy remains a foundational treatment for many cancers but is often limited by its toxicity, which harms healthy cells and can lead to anemia, infections, and disruptions in treatment schedules. If AU2-94’s protective properties prove effective in patients, it may enable longer and more consistent chemotherapy regimens.

While the development of AU2-94 marks a notable advance, Professor Wang emphasized the need for additional funding to support the upcoming clinical trials that will assess the drug’s safety and efficacy in humans. "Funding is a major bottleneck. We need support to establish whether these promising findings can become meaningful benefits," she said.

This breakthrough adds to Professor Wang’s ongoing contributions to experimental cancer therapies. She was recently honored with a Top Innovator award for her role in developing aucleciclib, a drug that has shown encouraging results in treating advanced brain tumors and pancreatic cancer, with further trials underway for various cancers including breast, lung, ovarian, and colorectal.

The development of AU2-94 highlights the complex and lengthy process of creating new cancer medicines, requiring extensive research and collaboration. Researchers remain hopeful that this drug will offer new hope to patients facing aggressive and difficult-to-treat cancers.